Non-small Cell Lung Cancer (NSCLC)
Conditions
Brief summary
Present study is aimed at investigating potential molecular predictors of sensitivity or resistance to single-agent pemetrexed in the ≥ second line setting in a large cohort of advanced non-small cell lung cancer (NSCLC) patients. The following biomarkers will be investigated with either immunohistochemistry, fluorescence in situ hybridization or genotyping: thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyl transferase (GARFT), aminoimidazole carboxamide ribonucleotide formyltransferase (ATIC/AICARFT), epidermal growth factor receptor (EGFR), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS), v-myc myelocytomatosis viral oncogene homolog (MYC) and phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA).
Interventions
None listed
Sponsors
Armando Santoro, MD
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed diagnosis of advanced non-small cell lung cancer - Tumor tissue available at our institution * Patients treated with single agent pemetrexed for metastatic disease * Availability of full clinical data
Exclusion criteria
* Cytological diagnosis of advanced Non-small cell lung cancer * Lack of tumor tissue at our institution * Lack of full clinical data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association of each biomarker with treatment outcome in terms of response rate, time to progression, overall survival. | one year |
Secondary
| Measure | Time frame |
|---|---|
| Association of each biomarker with clinico-pathological features: histology, gender, age, smoking status, response to previous chemotherapy. | one year |
Countries
Italy
Outcome results
None listed